Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy at two UMEC doses in healthy subjects

被引:0
|
作者
Henderson, A.
Allen, A.
Gupta, A.
Renaux, J.
Brealey, N.
机构
关键词
Bronchodilators; COPD; -; management; Pharmacology;
D O I
暂无
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
P938
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy in healthy subjects
    Allen, A.
    Henderson, A.
    Gupta, A.
    Renaux, J.
    Brealey, N.
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [2] Characterization of Patients with Asthma Initiating Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
    Wrobleski, Kristin
    Noorduyn, Stephen
    Lee, Lydia
    Igboekwe, Emmeline
    Liu, Meixia
    Veeranki, Phani
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB101 - AB101
  • [3] Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
    Ismaila, Afisi S.
    Haeussler, Katrin
    Czira, Alexandrosz
    Youn, Ji-Hee
    Malmenas, Mia
    Risebrough, Nancy A.
    Agarwal, Jatin
    Nassim, Maria
    Sharma, Raj
    Compton, Chris
    Vogelmeier, Claus F.
    Han, MeiLan K.
    Halpin, David M. G.
    ADVANCES IN THERAPY, 2022, 39 (09) : 3957 - 3978
  • [4] Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
    Afisi S. Ismaila
    Katrin Haeussler
    Alexandrosz Czira
    Ji-Hee Youn
    Mia Malmenäs
    Nancy A. Risebrough
    Jatin Agarwal
    Maria Nassim
    Raj Sharma
    Chris Compton
    Claus F. Vogelmeier
    MeiLan K. Han
    David M. G. Halpin
    Advances in Therapy, 2022, 39 : 3957 - 3978
  • [5] BENEFIT-RISK PROFILES OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) VS UMEC/VI IN PATIENTS WITH COPD: A MARKOV MODEL
    Bratton, Daniel
    Hartley, Benjamin
    Barnes, Neil
    Brusselle, Guy
    Compton, Christopher
    Corbridge, Thomas
    Dransfield, Mark
    Halpin, David
    Han, Meilan
    Jones, Christine Elaine
    Jones, Paul
    Lange, Peter
    Lipson, David
    Martinez, Fernando
    Papi, Alberto
    Roche, Nicolas
    Singh, Dave
    Wise, Robert
    CHEST, 2020, 158 (04) : 1666A - 1671A
  • [6] Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
    Sandeep Bansal
    Martin Anderson
    Antonio Anzueto
    Nicola Brown
    Chris Compton
    Thomas C. Corbridge
    David Erb
    Catherine Harvey
    Morrys C. Kaisermann
    Mitchell Kaye
    David A. Lipson
    Neil Martin
    Chang-Qing Zhu
    Alberto Papi
    npj Primary Care Respiratory Medicine, 31
  • [7] Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
    Bansal, Sandeep
    Anderson, Martin
    Anzueto, Antonio
    Brown, Nicola
    Compton, Chris
    Corbridge, Thomas C.
    Erb, David
    Harvey, Catherine
    Kaisermann, Morrys C.
    Kaye, Mitchell
    Lipson, David A.
    Martin, Neil
    Zhu, Chang-Qing
    Papi, Alberto
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2021, 31 (01)
  • [8] Population pharmacokinetic (PK) analysis of fluticasone furoate (FF)/umeclidimium (UMEC)/vilanterol (VI) via a single inhaler in patients with COPD (FULFIL)
    Mehta, Rashmi
    Pefani, Eleni
    Beerahee, Misba
    Barnacle, Helen
    Birk, Ruby
    Brealey, Noushin
    Zhu, Chang-Qing
    Lipson, David A.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [9] An Analysis of the IMPACT Trial Assessing Single-Inhaler Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI Using a Composite Adverse Event Outcome in Patients with COPD
    Wells, J. M.
    Bhatt, S. P.
    Carr, T. F.
    Criner, G. J.
    Halpin, D. M. G.
    Han, M. K.
    Jain, R.
    Kaye, M. G.
    Kraft, M.
    Lipson, D. A.
    Mapel, D.
    Mammen, M. J.
    McEvoy, C.
    Midwinter, D.
    Singh, D.
    Wise, R.
    Dransfield, M. T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [10] Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis”
    Jonathan Marshall
    Akanksha Sharma
    Patrick Darken
    Mario Ouwens
    Barinder Singh
    Deniz Tansey-Dwyer
    Advances in Therapy, 2023, 40 : 2549 - 2555